CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous lymphoproliferative disorder.
• Distinct variants include plasmablastic lymphoma, primary effusion lymphoma, and HHV-8-associated multicentric Castleman disease-related DLBCL.
• These lymphomas present diagnostic and therapeutic challenges due to lack of CD20 expression, atypical morphology, and aggressive behavior.

Purpose of the Study:

• To review the biology of CD20-negative DLBCL variants.
• To outline potential future therapeutic strategies.
• To enhance awareness of these rare malignancies among healthcare professionals.

Main Methods:

• Literature review of existing preclinical and clinical data.
• Synthesis of current knowledge on CD20-negative DLBCL biology.
• Identification of emerging therapeutic targets and approaches.

Main Results:

• Summarizes distinct biological features of CD20-negative DLBCL variants.
• Highlights challenges in diagnosis and treatment, including chemotherapy resistance.
• Identifies areas for future research and clinical investigation.

Conclusions:

• CD20-negative DLBCLs are aggressive and challenging malignancies.
• Further research is needed to develop targeted therapies.
• Increased awareness and understanding are crucial for improved patient outcomes.